Bone and Mineral Metabolism

SY49-03 - Strategies to Mitigate Bone Loss After Denosumab Cessation – Current and Future Perspectives

Monday, June 15, 2026

11:30 AM - 12:00 PM CT

Location: Room W375B

Symposium Speaker(s)

Bente Langdahl, MD, PhD, DMSc

Professor
Aarhus University Hospital
Aarhus N, Denmark

Disclosure(s):

Bente Langdahl, MD, PhD, DMSc: Amgen: Advisory Board (), Speakers' Bureau (); Angitia: Advisory Board (); Gedeon-Richter: Advisory Board (), Speakers' Bureau (); Mereo: Advisory Board (); Samsung-Bioepis: Advisory Board (); Sandoz: Speakers' Bureau (); UCB: Advisory Board (), Speakers' Bureau ()

This session characterizes the clinical problem of post-denosumab rebound, provides a comprehensive update on human studies examining the use of bisphosphonates following denosumab and explores mechanistic insights from preclinical studies that will be critical in the design of definitive human trials.